REMEGEN
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Public
- Established
- 2008-07-04
- Employees
- 3.4K
- Market Cap
- -
- Website
- http://www.remegen.com
- Introduction
The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical value for major diseases such as autoimmunity, oncology, and ophthalmology. The company is an innovative biopharmaceutical company with a global perspective. Since its establishment, it has been focusing on therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and double antibodies. Main products: tetacip, vidicetumab, RC28, RC88, RC98, RC108, RC118, RC148, RC198, etc.
A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05687526
- Locations
- 🇨🇳
Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Chengdu Women's & Children's Central Hospital, Chengdu, Sichuan, China
A Study of Telitacicept in Lupus Nephritis
- Conditions
- Lupus Nephritis
- Interventions
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05680480
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳Affiliated Hospital of Hebei University, Baoding, Hebei, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
- Conditions
- Primary Sjogren's Syndrome
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 375
- Registration Number
- NCT05673993
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT05628857
- Locations
- 🇨🇳
Beijing Cancer Hopspital, Beijing, Beijing, China
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05514158
- Locations
- 🇨🇳
Remegen, Beijing, Beijing, China
A Study to Assess the Safety and Tolerability of RC88 for Patients with Advanced Solid Tumours
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT05508334
- Locations
- 🇨🇳
Remegen, Beijing, Beijing, China
🇨🇳Remgenen, Beijing, Beijing, China
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Biological: Placebo
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT05306574
- Locations
- 🇬🇹
Guatemala site, Guatemala, Guatemala
🇺🇸Orange Site, Orange, California, United States
🇲🇺Quatre Bornes Site, Quatre Bornes, Mauritius
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
- Conditions
- Urothelial CarcinomaHER2-expressing
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 452
- Registration Number
- NCT05302284
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05297552
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Biological: TelitaciceptDrug: standard therapy
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 92
- Registration Number
- NCT05247203
- Locations
- 🇨🇳
Affiliated Hospital of Hebei University, Baoding, Hebei, China
🇨🇳The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Xiangya Hospital, Central South University, Changsha, Hunan, China